ProKidney Corp.
James Coulston has extensive work experience in finance and accounting. James is currently serving as the CFO at ProKidney Corp. since February 2019. Prior to this, they worked as the Executive Director of Finance at Banner Life Sciences from August 2015 to January 2019. Before that, they held the position of Senior Director of Finance and Controller at Targacept, Inc. from July 2007 to August 2015. James also worked at BB&T as the VP of Accounting Policy Manager in 2006 and at Ernst & Young LLP as an Audit Manager from 1999 to 2006.
James Coulston obtained a Bachelor of Science (BS) degree in Accounting from North Carolina State University in 1998. James then pursued a Master's degree in Accounting from the same university between 1998 and 1999. Apart from their formal education, James also holds a Certified Public Accountant (CPA) certification. There is no specific information available regarding any other formal education or certifications.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.